Orphanet Journal of Rare Diseases | Social Pharmaceutical Innovations Addressing Challenges in Rare Disease Drug Access

Recommend:

This study systematically analyzes innovative initiatives in multiple countries to address the accessibility of orphan drugs, revealing how Social Pharmaceutical Innovations (SPINs) break through traditional R&D models and improve the availability, accessibility, and affordability of treatments.

 

Literature Overview
This article, 'How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases', published in the Orphanet Journal of Rare Diseases, reviews and summarizes how Social Pharmaceutical Innovations (SPINs) have improved drug accessibility for rare diseases in various regions (Brazil, Canada, France, Netherlands) through multi-stakeholder collaboration, data governance, and novel production methods. The article focuses on the role of SPINs in drug development, regulation, pricing, and payment mechanisms, and how they challenge the existing pharmaceutical innovation system. Based on 151 semi-structured interviews and multiple case studies, it reveals how SPINs redefine pharmaceutical innovation networks, transform data collection practices, and provide new treatment pathways for patients.

Background Knowledge
Rare diseases affect approximately 470 million people globally, yet only 4-5% of these diseases have available treatments. Due to small patient populations, disease severity, and lack of controls, traditional randomized controlled trials (RCTs) are difficult to conduct, while high drug prices further limit insurance coverage and patient access. The current pharmaceutical innovation system is primarily market-driven, leading to delays in rare disease drug development. This article proposes Social Pharmaceutical Innovations (SPINs) as an alternative model, characterized by non-profit orientation, multi-stakeholder collaboration, local production, and data governance innovation. The study covers cases from multiple countries, including ANVISA 205/2017 accelerated approval in Brazil, G4RD genomics platform in Canada, AFM-led gene therapy collaboration in France, and CUREiHUS and myTomorrows platforms in the Netherlands. These cases not only demonstrate how SPINs overcome traditional R&D bottlenecks but also illustrate how innovation in policy, technology, and collaboration improves patient outcomes.

 

A tool to preliminarily predict phenotypes resulting from gene knockout before designing experiments.

Learn More

 

Research Methods and Design
The research team employed a multi-case study design, selecting 15 SPIN cases from Brazil, Canada, France, and the Netherlands. Using qualitative methods including semi-structured interviews, stakeholder meeting participation, and literature analysis, the researchers examined how SPINs address challenges in drug development and accessibility for rare diseases from the perspectives of collaboration mechanisms, data collection, and patient treatment pathways.

Key Findings and Insights

• SPINs restructure pharmaceutical innovation networks by introducing non-traditional stakeholders such as patient organizations, public research institutions, and social investors, making the R&D process more diverse and collaborative.
• SPINs change data collection practices by utilizing real-world data, longitudinal studies, and clinician-led data generation, thereby compensating for the limitations of randomized controlled trials.
• SPINs significantly enhance patient access to treatments and reduce drug costs through localized manufacturing, risk-sharing agreements, and hospital exemption mechanisms.
• The study found that SPIN models adapt to national policy and regulatory environments, forming unique innovation pathways, thus limiting replicability and requiring localized adaptation.
• While SPINs cannot fully replace the traditional pharmaceutical innovation system, they offer a novel conceptual and practical framework for improving access to rare disease treatments.

Implications and Future Directions
This study provides theoretical support and practical examples for innovation systems in rare disease treatment. Future research should explore how to institutionalize SPINs at the national level, including data governance, intellectual property sharing, and non-profit economic models.

 

A practical tool for rapidly mapping DNA or RNA sequences to the genome.

Learn More

 

Conclusion
Social Pharmaceutical Innovations (SPINs) are emerging as a critical approach to addressing the challenges of rare disease drug accessibility. Through multi-country case studies, this article demonstrates the potential of SPINs in redefining pharmaceutical innovation networks, transforming data collection and usage, and offering new treatment options for patients. Although SPINs cannot yet fully replace the traditional pharmaceutical innovation system, they offer significant advantages in localized R&D, multi-stakeholder collaboration, and non-market-driven mechanisms. Future research should focus on how to institutionalize these innovations for broader and sustainable impact. A conclusion of about 300 words should summarize the core findings, innovations, implications for the industry, and future research directions.

 

Conor M W Douglas, Tineke Kleinhout-Vliek, Rob Hagendijk, Shir Grunebaum, and Ellen Moors. How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases. Orphanet Journal of Rare Diseases.